摘要
The last decade has seen remarkable advances in the treatment of prostatecancer. Until 2010, only docetaxel had demonstrated the ability to improve the survival in metastatic castration-resistant prostate cancer （mCRPC）.
The last decade has seen remarkable advances in the treatment of prostatecancer. Until 2010, only docetaxel had demonstrated the ability to improve the survival in metastatic castration-resistant prostate cancer （mCRPC）.
